Business Context and Reporting Period
Company: Bruker Corporation (BRKR)
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2021
Context: The filing serves as a Regulation FD disclosure in advance of the Jefferies Virtual Healthcare Conference. It provides preliminary, unaudited management expectations for the second quarter and full fiscal year 2021.
Key Financial Metrics
This filing focuses on forward-looking non-GAAP organic revenue growth expectations rather than historical GAAP financial statements. Specific values for revenue, profit, cash flow, margins, debt, or liquidity are not provided in this document.
- Q2 2021 Non-GAAP Organic Revenue Growth: Expected to be greater than 25% compared to Q2 2020.
- Fiscal Year 2021 Non-GAAP Organic Revenue Growth: Expected to be in the range of 13% to 15% compared to fiscal year 2020.
Material Changes Versus Prior Period
The Company has increased its full-year 2021 non-GAAP organic revenue growth guidance by 2% compared to prior guidance. This adjustment is attributed to continued strong demand for high-performance life science tools, scientific instruments, and diagnostic solutions.
Guidance, Outlook, and Risks
Management Commentary: Management attributes the positive outlook to robust demand for its core product lines. The figures provided are based on preliminary analysis and are subject to adjustment during the quarter-end and year-end closing procedures.
Non-GAAP Measures: The filing defines "organic revenue" as GAAP revenue excluding the effects of foreign currency translation, acquisitions, and divestitures. The Company states it cannot provide a reconciliation to the most directly comparable GAAP measure on a forward-looking basis without unreasonable effort.
Risks and Contingencies:
- Results are preliminary and unaudited; material adjustments may occur during the closing process.
- Forward-looking statements are subject to risks including the global economy and the COVID-19 pandemic.
- The Company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the final audited Q2 2021 and full-year 2021 results in the subsequent Form 10-Q and Form 10-K filings to confirm if preliminary expectations were met.
- Review the reconciliation of non-GAAP organic revenue to GAAP revenue in future filings to understand the impact of currency and acquisitions.
- Monitor updates regarding the impact of the COVID-19 pandemic on the supply chain and demand for scientific instruments.
- Confirm the specific components of the 2% guidance increase in the official earnings release.